Plerixafor and abbreviated-course granulocyte colony-stimulating factor for mobilizing hematopoietic progenitor cells in light chain amyloidosis

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 12, 2014, Pages 1926-1931

  Dhakal, Binod ^a   Strouse, Christopher ^a   D'Souza, Anita ^a   Arce Lara, Carlos ^a   Esselman, Jeanie ^a   Eastwood, Daniel ^a   Pasquini, Marcelo ^a   Saber, Wael ^a   Drobyski, William ^a   Rizzo, J Douglas ^a   Hari, Parameswaran N ^a   Hamadani, Mehdi ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Granulocyte colony stimulating factor (G CSF); Light chain amyloidosis (AL amyloidosis); Plerixafor; Stem cell mobilization

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIBIOTIC AGENT; BORTEZOMIB; CREATININE; GRANULOCYTE COLONY STIMULATING FACTOR; LENALIDOMIDE; PLERIXAFOR; TROPONIN T; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HETEROCYCLIC COMPOUND;

ADULT; AGED; AMYLOIDOSIS; APHERESIS; APHERESIS DEVICE; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; CAUSE OF DEATH; CD34 T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DRUG EFFICACY; ENGRAFTMENT; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; GRANULOCYTE; HEART ARREST; HEART ARRHYTHMIA; HEART FAILURE; HEMATOPOIETIC STEM CELL; HOSPITALIZATION; HUMAN; HYPOTENSION; KARNOFSKY PERFORMANCE STATUS; LIGHT CHAIN AMYLOIDOSIS; MALE; MORTALITY; NAUSEA; NEUTROPENIA; NEUTROPHIL; OVERALL SURVIVAL; PLASMACYTOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; STEM CELL MOBILIZATION; T LYMPHOCYTE; WEIGHT GAIN; AUTOGRAFT; BLOOD; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED;

ADULT; AGED; AMYLOIDOSIS; ANTI-HIV AGENTS; AUTOGRAFTS; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED;

EID: 84912142377     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.08.002     Document Type: Article

References (35)

1. Falk R.H., Comenzo R.L., Skinner M. The systemic amyloidoses. NEngl J Med 1997, 337:898-909.
2. Dispenzieri A., Kyle R.A., Lacy M.Q., et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004, 103:3960-3963.
3. Cibeira M.T., Sanchorawala V., Seldin D.C., et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011, 118:4346-4352.
4. Schonland S.O., Dreger P., de Witte T., Hegenbart U. Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. Bone Marrow Transplant 2012, 47:895-905.
5. Girnius S., Seldin D.C., Meier-Ewert H.K., et al. Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement. Bone Marrow Transplant 2014, 49:434-439.
6. Lachmann H.J., Wechalekar A.D., Gillmore J.D. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. NEngl J Med 2008, 358:91-92. author reply 92-3.
7. Kumar S.K., Gertz M.A., Lacy M.Q., et al. Recent improvements in survival in primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin Proc 2011, 86:12-18.
8. Dispenzieri A., Seenithamby K., Lacy M.Q., et al. Patients with immunoglobulin light chain amyloidosis undergoing autologous stem cell transplantation have superior outcomes compared with patients with multiple myeloma: a retrospective review from a tertiary referral center. Bone Marrow Transplant 2013, 48:1302-1307.
9. Merlini G., Wechalekar A.D., Palladini G. Systemic light chain amyloidosis: an update for treating physicians. Blood 2013, 121:5124-5130.
10. Gertz M.A. Immunoglobulin light chain amyloidosis: 2013 update on diagnosis, prognosis, and treatment. Am J Hematol 2013, 88:416-425.
11. Comenzo R.L. How I treat amyloidosis. Blood 2009, 114:3147-3157.
12. Comenzo R.L., Vosburgh E., Falk R.H., et al. Dose-intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998, 91:3662-3670.
13. Mollee P.N., Wechalekar A.D., Pereira D.L., et al. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant 2004, 33:271-277.
14. Devine S.M. Re-examining the role of high-dose chemotherapy in the treatment of light chain amyloidosis. Biol Blood Marrow Transplant 2014, 20:14-19.
15. Jaccard A., Moreau P., Leblond V., et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. NEngl J Med 2007, 357:1083-1093.
16. Bashir Q., Langford L.A., Parmar S., et al. Primary systemic amyloid light chain amyloidosis decompensating after filgrastim-induced mobilization and stem-cell collection. JClin Oncol 2011, 29:e79-80.
17. Comenzo R.L., Sanchorawala V., Fisher C., et al. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 1999, 104:553-559.
18. Benson M.D., Kincaid J.C. The molecular biology and clinical features of amyloid neuropathy. Muscle Nerve 2007, 36:411-423.
19. Leung N., Leung T.R., Cha S.S., et al. Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients. Blood 2005, 106:3353-3357.
20. Perotti C., Del Fante C., Viarengo G., et al. Peripheral blood progenitor cell mobilization and collection in 42 patients with primary systemic amyloidosis. Transfusion 2005, 45:1729-1734.
21. Fricker S.P. Physiology and pharmacology of plerixafor. Transfus Med Hemother 2013, 40:237-245.
22. DiPersio J.F., Stadtmauer E.A., Nademanee A., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
23. DiPersio J.F., Micallef I.N., Stiff P.J., et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. JClin Oncol 2009, 27:4767-4773.
24. Sutherland D.R., Anderson L., Keeney M., et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. JHematother 1996, 5:213-226.
25. Levering W.H., Preijers F.W., van Wieringen W.N., et al. Flow cytometric CD34+ stem cell enumeration: lessons from nine years' external quality assessment within the Benelux countries. Cytometry B Clin Cytom 2007, 72:178-188.
26. Skinner M., Sanchorawala V., Seldin D.C., et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004, 140:85-93.
27. Sanchorawala V. Role of high-dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis. Am J Blood Res 2012, 2:9-17.
28. Saba N., Sutton D., Ross H., et al. High treatment-related mortality in cardiac amyloid patients undergoing autologous stem cell transplant. Bone Marrow Transplant 1999, 24:853-855.
29. Attal M., Harousseau J.L., Facon T., et al. Single versus double autologous stem-cell transplantation for multiple myeloma. NEngl J Med 2003, 349:2495-2502.
30. Porrata L.F., Gertz M.A., Litzow M.R., et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res 2005, 11:1210-1218.
31. Dunn D., Vikas P., Jagasia M., Savani B.N. Plerixafor in AL amyloidosis: improved graft composition and faster lymphocyte recovery after auto-SCT in patient with end-stage renal-disease. Bone Marrow Transplant 2012, 47:1136-1137.
32. Micallef I.N.M., Stiff P.J., Maziarz R.T., et al. Comparison of graft durability among lymphoma patients who received plerixafor in combination with G-CSF for primary versus failed mobilization. Biol Blood Marrow Transplant 2009, 15:S11.
33. Awan F., Kochuparambil S.T., Falconer D.E., et al. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplant 2013, 48:1279-1284.
34. Costa L.J., Alexander E.T., Hogan K.R., et al. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011, 46:64-69.
35. Varmavuo V., Mantymaa P., Kuittinen T., et al. Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: potential implications for apheresis and graft composition. Transfus Apher Sci 2012, 46:257-262.